Surgical Repair vs. Non-Surgical Treatment for Rotator Cuff Tears: Is Surgery Worth the Cost?

By HEOR Staff Writer

January 28, 2023

The rotator cuff, a critical component of the shoulder, plays a crucial role in stabilising the joint and facilitating arm movement. When it tears, patients face a decision: to opt for surgical repair or non-surgical treatment. This rotator cuff repair analysis presents a detailed review of both methods, shedding light on their effectiveness, safety, and cost-effectiveness.

Understanding Rotator Cuff Tears

Low-to-moderate-certainty evidence suggests that surgical repair does not result in clinically relevant differences in effect compared to non-surgical treatment for degenerative rotator cuff tears. An HTA from the Norwegian institute of public health showed that choosing exclusively non-surgical treatment over surgery can provide up to NOK 81 million in annual cost savings.

Research suggests that there are no clinically relevant differences in effect between surgical and non-surgical treatment. Few serious adverse events were reported, but we are uncertain about the absolute risks. Surgery is the most expensive alternative, and choosing non-surgical treatment over surgery can provide significant cost savings.

Reference url

Recent Posts

EU Alzheimer Approval Challenges: Anavex Withdraws Blarcamesine Application Amid Regulatory Hurdles

By João L. Carapinha

March 26, 2026

Anavex Life Sciences has withdrawn its marketing authorization application for blarcamesine in early Alzheimer’s disease following feedback from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP). EU Alzheimer Approval Challenges remain a significant hurdle for ...
South Africa Health Reform: Revitalizing the Crisis-Stricken Sector
South Africa health reform is urgently needed to reverse the deepening crisis in the country’s public and private health sectors. Sustained real-term declines in public per-capita spending, massive provincial debt, critical staff shortages, and uncontrolled private-sector cost escalation are coll...
NICE Pembrolizumab Recommendation for Locally Advanced Head and Neck Cancer Treatment

By HEOR Staff Writer

March 25, 2026

NICE Pembrolizumab recommendation offers a major advance for adults with resectable locally advanced head and neck squamous cell carcinoma. This update provides an evidence-based overview of the final draft guidance issued by NICE recommending pembrolizumab, within its marketing authorisation, fo...